Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III desmoteplase in acute ischemic stroke (3–9 hours window)
2008-000622-40Phase 3Terminated
- Sponsor
- Lundbeck
- Start
- Sep 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing desmoteplase 90 µg/kg with placebo (2 arms). Primary endpoint: Favourable outcome at Day 90. Started Sep 2008; status: terminated.
02
Drugs
desmoteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2008-000622-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000622-40.